Endocrine Abstracts

Large databases facilitate the examination of those factors, which may determine response to treatment, potentially to develop prediction models. We have used KIMS (Pfizer's international metabolic database of GH-treated adults), to examine parameters that might predict clinical response to GH therapy in hypopituitary adults.Patients/methods: Patients with non-functioning pituitary adenoma on GH titrated to maintain serum IGF-I between minus 2 and 2 SDS,...

Continuous administration of 400 μg/day of letrozole (LET), a non-steroidal inhibitor of P450 aromatase, with start pre-pubertally to female rats, induces hyperandrogenemia and reproductive abnormalities similar to those observed in women with polycystic ovary syndrome (PCOS). However, these rats do not develop metabolic abnormalities, despite high circulating testosterone. A possible explanation may be that the dose was too high and thus completely inhibited the estrogen...

Objective: Few studies have determined the effects of more than 5-10 years of GH replacement in adults on body composition and metabolic parameters.Design/Patients: In this prospective, single-center, open-label study, the effects of 15 years of GH replacement on body composition and metabolic parameters were determined in 156 hypopituitary adults (93 men) with adult onset GH deficiency (GHD). Mean age was 50.5 (range 22–74) years at study start. Bo...

Objective: Few studies have determined the effects of more than 5–10 years of GH replacement in adults on bone mass and density.Design/patients: In this prospective, single-centre, open-label study, the effects of 15 years of GH replacement on bone mineral content (BMC) and bone mineral density (BMD) were determined in 126 hypopituitary adults (72 men) with adult onset GH deficiency (GHD). Mean age was 49.4 (range 22–74) years at study start. B...

Context: The effect of GH replacement in elderly GH deficient (GHD) adults on bone mineral density (BMD) is not known.Objective: In this prospective, single-centre, open-label study, the effects of 3-year GH replacement were determined in 45 GHD adults above 65 years of age and in 45 younger GHD patients with a mean age of 39.5 (S.E.M. 1.1) years. All patients had adult onset disease and both groups were comparable in terms of number of an...

Context: Little is known of the importance of previous irradiation therapy for baseline characteristics and responsiveness to GH replacement in GH deficient (GHD) adults.Objective/design/patients: In this prospective, single-centre, open-label study, the effects of 10-year GH replacement on metabolic variables and safety were determined in 18 GHD adults that had previously received pituitary irradiation therapy and 18 non-irradiated GHD patients. All pat...